Article Text

Download PDFPDF
Child health
Further evidence from a large US electronic health record-based study that some children and adolescents can develop postacute sequelae of SARS-CoV-2 infection
  1. Danilo Buonsenso
  1. Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
  1. Correspondence to Dr Danilo Buonsenso, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Roma, Italy; danilobuonsenso{at}gmail.com

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: Rao S, Lee GM, Razzaghi H, Lorman V, Mejias A, Pajor NM, Thacker D, Webb R, Dickinson K, Bailey LC, Jhaveri R, Christakis DA, Bennett TD, Chen Y, Forrest CB. Clinical Features and Burden of Postacute Sequelae of SARS-CoV-2 Infection in Children and Adolescents. JAMA Pediatr 2022;176:1000–1009. doi: 10.1001/jamapediatrics.2022.2800.

Implications for practice and research

  • This study provides further evidence that a subgroup of children (about 3%) and adolescents develop postacute sequelae (PASC) other than multitystem inflammatory syndrome in children (MIS-C) after SARS-CoV-2 infection.

  • There is urgent need to implement to identify diagnostics, biomarkers and potential therapeutics of PASC.

Context

There is a growing body of evidence that a subgroup of children and adolescents do not fully recover from acute SARS-CoV-2 infection, but can develop a cohort of persisting signs and symptoms otherwise unexplained by routine diagnostics.1 This condition is known as PASC, or postcovid condition or Long Covid. However, available studies were mostly limited by either lack of control groups, small …

View Full Text

Footnotes

  • Competing interests The author received a grant to study Long Covid in children by Pfizer and Roche Italia.

  • Provenance and peer review Commissioned; internally peer reviewed.